Coherus Oncology (CHRS) Liabilities and Shareholders Equity (2013 - 2026)

Coherus Oncology has disclosed Liabilities and Shareholders Equity across 14 years of filings, most recently posting $266.0 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $266.0 million, down 28.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 25.96% YoY), and the FY2025 annual result was $258.3 million, down 42.4% from the prior year.
• Liabilities and Shareholders Equity came in at $266.0 million for Q1 2026 at Coherus Oncology, up from $258.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $763.5 million in Q1 2024 to a low of $258.3 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $505.0 million (2024), against an average of $500.0 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 89.74% in 2024 and sank 51.4% in 2025, its largest moves.
• Coherus Oncology's Liabilities and Shareholders Equity stood at $480.8 million in 2022, then jumped by 30.94% to $629.6 million in 2023, then retreated by 28.76% to $448.5 million in 2024, then tumbled by 42.4% to $258.3 million in 2025, then advanced by 2.97% to $266.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $266.0 million (Q1 2026), $258.3 million (Q4 2025), and $516.5 million (Q3 2025), per Business Quant data.